Genedrive is a biotechnology company focused on developing point-of-care pharmacogenetic tests that aim to enhance clinical outcomes in time-critical situations. Their flagship products include the Genedrive CYP2C19 ID Kit, which is designed to quickly determine a patient's metabolizer status, and the Genedrive MT-RNR1 ID Kit, recognized as the world's first point-of-care genetic test aimed at reducing the risk of aminoglycoside-induced hearing loss. These innovative tests are intended to be user-friendly and facilitate rapid decision-making in clinical settings, thereby improving patient care.

The company's mission emphasizes the importance of accessibility and efficiency in genetic testing, particularly in urgent medical contexts. By providing healthcare professionals with the tools to make informed decisions based on genetic information, Genedrive seeks to address critical health challenges and optimize treatment strategies. Their commitment to advancing pharmacogenetic testing reflects a broader trend in personalized medicine, where treatments can be tailored to individual genetic profiles, ultimately leading to better health outcomes.

United Kingdom

genedrive plc is a molecular diagnostics company developing and commercialising a low-cost, rapid, versatile, simple to use and robust point of need molecular platform for use in patient stratification (genotyping). We are passionate about the opportunity to build a sustainable business around molecular diagnostics and to play an important role in the diagnostic and treatment challenges presented by global health issues. 

The company launched the Genedrive MT-RNR1 ID Kit, a pharmacogenetic test to prevent antibiotic induced deafness in infants, which was co-developed with the partners in the UK's National Health Service and is now used for routine clinical use.

Genedrive

Company Details